D-2-HG Gene Circuit Control for Tumor-Responsive Transgene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and targeting tumor cells with IDH mutations face challenges due to limited markers, transport restrictions, and the difficulty of chemical probes reaching tumor sites, necessitating a more effective means to sense and respond to the tumor metabolite D-2-hydroxyglutarate (D-2-HG).
Innovation Solution
A control system for inducing transgene expression using D-2-HG, comprising recombinant transcriptional repressors, D-2-HG inducible promoters, and sequences to be transcribed, which can be classified into high- and low-concentration systems, enabling the development of living cell sensors, suicide gene therapy products, and therapeutic cells that respond to D-2-HG concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If chemical molecular probes are used for D-2-HG detection, then detection can be performed in vivo, but the probes cannot accurately reach tumor sites due to transport restrictions and massive dilution
Solution Approach 1:
The patent uses engineered living cells as intermediaries between the detection system and the tumor target. These cells express D-2-HG sensors and can actively migrate to tumor sites, serving as a living vehicle that overcomes the transport and dilution problems of chemical probes while maintaining detection accuracy
Solution Approach 2:
The engineered living cells are designed to autonomously navigate to tumor sites and perform detection without external assistance. The cells self-organize the detection process by expressing sensors, migrating autonomously, and amplifying signals at the target site, eliminating the need for external probe delivery systems
2Measurement precision
If engineered cells are used as living sensors, then sensitivity is greatly improved and active migration to tumor sites is achieved, but the system complexity increases significantly
Solution Approach 1:
The detection system is segmented into modular genetic components including D-2-HG sensor genes, promoter elements, reporter genes, and cell surface markers. This modular architecture allows independent optimization of each component and simplifies the engineering process despite the overall system complexity
Solution Approach 2:
The engineered living cells perform multiple functions simultaneously: they migrate to tumor sites, detect D-2-HG concentrations, amplify signals, and can be equipped with therapeutic functions. This multi-functionality consolidates what would otherwise require multiple separate systems into a single platform
3Adaptability or versatility
If a single detection system is used, then the design is simple, but it cannot meet specific needs for different D-2-HG concentrations and therapeutic applications
Solution Approach 1:
The patent creates detectable differences by modifying genetic parameters such as promoter strength, sensor expression levels, and reporter gene types. These parameter variations allow the system to be tuned for different D-2-HG concentration ranges and detection sensitivities without changing the fundamental system architecture
Solution Approach 2:
Different genetic configurations are applied to different cell populations or applications. For example, certain promoter-sensor-reporter combinations are optimized for high D-2-HG concentrations while others are designed for low concentrations, allowing each application to have locally optimized properties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system allows for high-sensitivity detection and targeted response to D-2-HG, enhancing diagnostic accuracy and therapeutic efficacy for tumors with IDH mutations, particularly in detecting small tumors and inducing targeted cell suicide or therapeutic functions.
Implementation Method 1
The control system comprises a recombinant transcriptional repressor, a D-2-HG inducible promoter and a sequence to be transcribed
Data Source
AI summary
A control system for inducing transgene expression by means of D-2-hydroxyglutarate (D-2-HG), which relates to the technical fields of synthetic biology, gene therapy and cell immunity. A sensing object of the control system is D-2-HG; and the control system is classified into a control system for inducing transgene expression by means of high-concentration D-2-HG (HGind-H) and a control system for inducing transgene expression by means of low-concentration D-2-HG (HGind-L). The control system includes a recombinant transcriptional repressor, a D-2-HG inducible promoter and a sequence to be transcribed. According to the present invention, the system is used to control a diagnostic gene circuit, a suicide gene circuit and an immune cell therapeutic gene circuit that respond to a tumor metabolite D-2-HG, thereby developing living cell sensors, suicide gene therapy products and cell therapy products with D-2-HG as key information.